Aranesp/Procrit Trial Tumor Biopsy Collection Not Feasible, Cmte. Says
This article was originally published in The Pink Sheet Daily
Executive Summary
FDA says erythropoietin clinical effect cannot be generalized to different tumor types without data from biopsies. Amgen's Aranesp will undergo five survival studies; J&J will look at Procrit and Eprex in metastatic breast cancer patients with an endpoint of progression-free survival.